Literature DB >> 21539392

GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonists.

Angela Kecskés1, Dilip K Tosh, Qiang Wei, Zhan-Guo Gao, Kenneth A Jacobson.   

Abstract

Previously, G protein-coupled receptor (GPCR) agonists were tethered from polyamidoamine (PAMAM) dendrimers to provide high receptor affinity and selectivity. Here, we prepared GPCR ligand--dendrimer (GLiDe) conjugates from a potent adenosine receptor (AR) antagonist; such agents are of interest for treating Parkinson's disease, asthma, and other conditions. Xanthine amine congener (XAC) was appended with an alkyne group on an extended C8 substituent for coupling by Cu(I)-catalyzed click chemistry to azide-derivatized G4 (fourth-generation) PAMAM dendrimers to form triazoles. These conjugates also contained triazole-linked PEG groups (8 or 22 moieties per 64 terminal positions) for increasing water-solubility and optionally prosthetic groups for spectroscopic characterization and affinity labeling. Human AR binding affinity increased progressively with the degree of xanthine substitution to reach K(i) values in the nanomolar range. The order of affinity of each conjugate was hA(2A)AR > hA(3)AR > hA(1)AR, while the corresponding monomer was ranked hA(2A)AR > hA(1)AR ≥ hA(3)AR. The antagonist activity of the most potent conjugate 14 (34 xanthines per dendrimer) was examined at the G(i)-coupled A(1)AR. Conjugate 14 at 100 nM right-shifted the AR agonist concentration--response curve in a cyclic AMP functional assay in a parallel manner, but at 10 nM (lower than its K(i) value), it significantly suppressed the maximal agonist effect in calcium mobilization. This is the first systematic probing of a potent AR antagonist tethered on a dendrimer and its activity as a function of variable loading.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21539392      PMCID: PMC3116093          DOI: 10.1021/bc1005812

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  42 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

2.  Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor.

Authors:  Athena M Keene; Ramachandran Balasubramanian; John Lloyd; Asher Shainberg; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

3.  A fluorescent ligand-binding alternative using Tag-lite® technology.

Authors:  Jurriaan M Zwier; Thomas Roux; Martin Cottet; Thierry Durroux; Stephanie Douzon; Sara Bdioui; Nathalie Gregor; Emmanuel Bourrier; Nadia Oueslati; Ludovic Nicolas; Norbert Tinel; Chloe Boisseau; Paul Yverneau; Fabienne Charrier-Savournin; Michel Fink; Eric Trinquet
Journal:  J Biomol Screen       Date:  2010-10-25

Review 4.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 5.  Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility.

Authors:  Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Stefania Gessi; Pier Andrea Borea
Journal:  Chem Rev       Date:  2008-01       Impact factor: 60.622

6.  2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CCPA)--a high affinity agonist radioligand for A1 adenosine receptors.

Authors:  K N Klotz; M J Lohse; U Schwabe; G Cristalli; S Vittori; M Grifantini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

7.  Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies.

Authors:  P G Baraldi; B Cacciari; S Moro; R Romagnoli; K A Jacobson; S Gessi; P A Borea; G Spalluto
Journal:  J Med Chem       Date:  2001-08-16       Impact factor: 7.446

8.  GPCR ligand-dendrimer (GLiDe) conjugates: future smart drugs?

Authors:  Kenneth A Jacobson
Journal:  Trends Pharmacol Sci       Date:  2010-10-18       Impact factor: 14.819

9.  A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists.

Authors:  K A Jacobson; R Xie; L Young; L Chang; B T Liang
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

10.  Opioid agonist and antagonist bivalent ligands as receptor probes.

Authors:  P S Portoghese; G Ronsisvalle; D L Larson; C B Yim; L M Sayre; A E Takemori
Journal:  Life Sci       Date:  1982 Sep 20-27       Impact factor: 5.037

View more
  11 in total

1.  Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A₂A and A₃ adenosine receptor ligands.

Authors:  Xiyan Hou; Mahesh S Majik; Kyunglim Kim; Yuna Pyee; Yoonji Lee; Varughese Alexander; Hwa-Jin Chung; Hyuk Woo Lee; Girish Chandra; Jin Hee Lee; Seul-Gi Park; Won Jun Choi; Hea Ok Kim; Khai Phan; Zhan-Guo Gao; Kenneth A Jacobson; Sun Choi; Sang Kook Lee; Lak Shin Jeong
Journal:  J Med Chem       Date:  2011-12-28       Impact factor: 7.446

2.  Synthesis of BODIPY derivatives substituted with various bioconjugatable linker groups: a construction kit for fluorescent labeling of receptor ligands.

Authors:  Fabian Heisig; Sabrina Gollos; Sven J Freudenthal; Ali El-Tayeb; Jamshed Iqbal; Christa E Müller
Journal:  J Fluoresc       Date:  2013-09-20       Impact factor: 2.217

3.  Click modification in the N6 region of A3 adenosine receptor-selective carbocyclic nucleosides for dendrimeric tethering that preserves pharmacophore recognition.

Authors:  Dilip K Tosh; Khai Phan; Francesca Deflorian; Qiang Wei; Lena S Yoo; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2012-01-11       Impact factor: 4.774

Review 4.  Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.

Authors:  Kenneth A Jacobson
Journal:  J Med Chem       Date:  2013-05-09       Impact factor: 7.446

Review 5.  Fluorescent ligands for adenosine receptors.

Authors:  Eszter Kozma; P Suresh Jayasekara; Lucia Squarcialupi; Silvia Paoletta; Stefano Moro; Stephanie Federico; Giampiero Spalluto; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2012-11-05       Impact factor: 2.823

6.  Modulation of G protein-coupled adenosine receptors by strategically functionalized agonists and antagonists immobilized on gold nanoparticles.

Authors:  P Suresh Jayasekara; Khai Phan; Dilip K Tosh; T Santhosh Kumar; Steven M Moss; Guofeng Zhang; Joseph J Barchi; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Purinergic Signal       Date:  2012-11-20       Impact factor: 3.765

7.  Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts.

Authors:  Tina C Wan; Dilip K Tosh; Lili Du; Elizabeth T Gizewski; Kenneth A Jacobson; John A Auchampach
Journal:  BMC Pharmacol       Date:  2011-10-31

8.  Programmable nanoscaffolds that control ligand display to a G-protein-coupled receptor in membranes to allow dissection of multivalent effects.

Authors:  Andrew V Dix; Steven M Moss; Khai Phan; Travis Hoppe; Silvia Paoletta; Eszter Kozma; Zhan-Guo Gao; Stewart R Durell; Kenneth A Jacobson; Daniel H Appella
Journal:  J Am Chem Soc       Date:  2014-08-25       Impact factor: 15.419

Review 9.  Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.

Authors:  Mine Silindir Gunay; A Yekta Ozer; Sylvie Chalon
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 10.  Application of Nanoparticles for Targeting G Protein-Coupled Receptors.

Authors:  Xin Ma; Yunfang Xiong; Leo Tsz On Lee
Journal:  Int J Mol Sci       Date:  2018-07-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.